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Abstract
Background: Atrial fibrillation (AF) is the most common dysrhythmia among elderly patients. A co-
morbidity associated with this disease process is embolic stroke. In an effort to reduce the potential morbidity
and mortality associated with stroke, patients are often placed on the anticoagulant warfarin. While warfarin
has been statistically proven to reduce the rate of embolic stroke in patients with AF, it potentiates increased
risk of bleeding. The elderly population has an elevated level of AF and increased risk for fall and bleeding
abnormalities. This systematic review aims to evaluate the risk versus benefit of prescribing warfarin in elderly
patients with AF.
Methods: A comprehensive database search was completed, using Medline, CINAHL and EBMR Multifile.
Inclusion criteria of English text, human trials, at least one study group with age > 70, atrial fibrillation,
warfarin use vs. no anticoagulation therapy, morbidity, mortality and hemorrhage were determined prior to
the search. In addition, exclusion criteria consisted of use of anticoagulation therapy following ablation
therapy or other surgical forms of AF management, studies which included patients with mechanical heart
valves or target INR >3 or study populations that were too narrowly drawn. Four articles were identified and
evaluated in this study. Validity was noted based on eight factors.
Results: All four articles reviewed were observational studies, with no randomized controlled trials. In total,
14 342 patients were analyzed between 1996 and 2007, with study duration from six to 28 months. All studies
took into account age and/or frailty in elderly patients with AF. Study groups varied from warfarin users to
non-users, all warfarin users of varying age and frail vs. non-frail warfarin users, and non-users. With regard to
general warfarin practices, two studies showed providers did not prescribe warfarin in the oldest and frailest
patients, and two studies found no variation in INR measures with age. When considering advancing age,
independent of warfarin therapy, two studies found a significant increase in stroke rate and one study found a
significant increase in death rate with advancing age. Three studies evaluated hemorrhage risk in relation to
increasing age independent of warfarin use, with one study finding a significant increase, one finding a non-
significant increase and one finding no difference. When evaluating the use of warfarin, one study displayed
no significant variation and one found a non-significant increase in hemorrhage rates for warfarin users with
advancing age. One study found a non-significant increase in hemorrhage with supratherapeutic warfarin use.
Conclusion: Throughout this systematic review, warfarin therapy does not prove to be more harmful than no
therapy, in elderly or frail patients with atrial fibrillation. Elderly and frail individuals are at a greater risk for
stroke, death and potentially hemorrhage independent of anticoagulant use. Additional research is necessary
in order to develop prescribing guidelines for warfarin therapy with consideration of age and frailty. It is
imperative that warfarin be prescribed and monitored carefully in all age ranges, in order to provide the most
effective prevention of embolic stroke while minimizing the risk of hemorrhage.
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Abstract   
 
Background:  Atrial fibrillation (AF) is the most common dysrhythmia among elderly 
patients.  A co-morbidity associated with this disease process is embolic stroke.  In an 
effort to reduce the potential morbidity and mortality associated with stroke, patients are 
often placed on the anticoagulant warfarin.  While warfarin has been statistically proven 
to reduce the rate of embolic stroke in patients with AF, it potentiates increased risk of 
bleeding.  The elderly population has an elevated level of AF and increased risk for fall 
and bleeding abnormalities.  This systematic review aims to evaluate the risk versus 
benefit of prescribing warfarin in elderly patients with AF.  
Methods:  A comprehensive database search was completed, using Medline, CINAHL 
and EBMR Multifile.  Inclusion criteria of English text, human trials, at least one study 
group with age > 70, atrial fibrillation, warfarin use vs. no anticoagulation therapy, 
morbidity, mortality and hemorrhage were determined prior to the search.  In addition, 
exclusion criteria consisted of use of anticoagulation therapy following ablation therapy 
or other surgical forms of AF management, studies which included patients with 
mechanical heart valves or target INR >3 or study populations that were too narrowly 
drawn. Four articles were identified and evaluated in this study.  Validity was noted 
based on eight factors. 
Results:  All four articles reviewed were observational studies, with no randomized 
controlled trials.  In total, 14 342 patients were analyzed between 1996 and 2007, with 
study duration from six to 28 months.  All studies took into account age and/or frailty in 
elderly patients with AF.  Study groups varied from warfarin users to non-users, all 
warfarin users of varying age and frail vs. non-frail warfarin users, and non-users.   
With regard to general warfarin practices, two studies showed providers did not prescribe 
warfarin in the oldest and frailest patients, and two studies found no variation in INR 
measures with age. 
When considering advancing age, independent of warfarin therapy, two studies found a 
significant increase in stroke rate and one study found a significant increase in death rate 
with advancing age.  Three studies evaluated hemorrhage risk in relation to increasing 
age independent of warfarin use, with one study finding a significant increase, one 
finding a non-significant increase and one finding no difference. 
When evaluating the use of warfarin, one study displayed no significant variation and one 
found a non-significant increase in hemorrhage rates for warfarin users with advancing 
age.  One study found a non-significant increase in hemorrhage with supratherapeutic 
warfarin use. 
Conclusion:  Throughout this systematic review, warfarin therapy does not prove to be 
more harmful than no therapy, in elderly or frail patients with atrial fibrillation.  Elderly 
and frail individuals are at a greater risk for stroke, death and potentially hemorrhage 
independent of anticoagulant use.  Additional research is necessary in order to develop 
prescribing guidelines for warfarin therapy with consideration of age and frailty.  It is 
imperative that warfarin be prescribed and monitored carefully in all age ranges, in order 
to provide the most effective prevention of embolic stroke while minimizing the risk of 
hemorrhage. 
Keywords:  Atrial Fibrillation, Elderly, Aged, Hemorrhage, Morbidity, Mortality 
 3 
Acknowledgements 
 
 To my family ~ Thank you for your patience, dedication, support and 
encouragement throughout my journey.  I would not have made it through the long hours 
of studying or the countless trials and triumphs without you! 
 4 
 
Table of Contents 
 
Biography …..….…………….…………………………………………………………..  1 
Abstract ….……..…………..…………………………………………………………..... 2 
Acknowledgements …………………………………………………………………….... 3 
Table of Contents …...……………..…………………………………………………….  4 
List of Tables …...…….…………….……………………………………………….......  5 
List of Figures ...….….…………………………………………………………………..  5 
List of Abbreviations…………………………………………………………………….  5 
Background……………………………….……………………………………………...  6 
Methods ……………..………………………..…………………………………………  8 
Search Strategy 
Validity Scoring      
Inclusion Criteria 
Exclusion Criteria 
Results ….………………..……………………………..………………………………....9 
Age and the Risk of Warfarin-Associated Hemorrhage: The ATRIA Study 
Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation 
People Aged Over 75 in Atrial Fibrillation on Warfarin 
The Impact of Frailty on the Utilization of Antithrombotic Therapy in Older Patients With Atrial Fibrillation 
Discussion………………………………………………………………………………  16 
Overview 
Validity 
Warfarin Prescribing Practices 
Variation in INR With Age 
Hemorrhage, Stroke and Death Risk With Increasing Age 
Hemorrhage Risk With Warfarin and Increasing Age 
New Warfarin Users 
Non-Therapeutic INR 
Study Limitations 
Conclusion……………………………………………………………………………...  22  
References………………………………………………………………………………  24 
Tables …………………………………………………………………………………..  26 
Figures…………………………………………………………………………………..  28 
 5 
List of Tables 
 
Table 1: CHADS2 Score and Interpretation 
 
Table 2: Validity Score 
 
Table 3: Article and Results Summary Matrix 
 
 
List of Figures 
 
 
Figure 1:    Article Selection flow diagram 
 
 
List of Abbreviations 
 
AF – Atrial Fibrillation 
ATRIA – Anticoagulation and Risk Factors in Atrial Fibrillation Study 
INR – International Normalized Ratio 
GI – Gastrointestinal  
 6 
Morbidity and Mortality With Warfarin Therapy Use 
in Elderly Patients With Atrial Fibrillation 
 
BACKGROUND 
 
The management of atrial fibrillation (AF) has been a topic of great debate 
throughout history.  Management options include, but are not limited to, the use of 
medications to control heart rate and heart rhythm, radiofrequency catheter ablation, 
chemical or electrical cardioversion, pacemakers and surgical occlusion of the left atrial 
appendage.1 
In addition to managing the disease process itself, a significant amount of 
research and health care effort is placed on reducing the symptoms and co-morbidities 
associated with AF.  Such consequences include thrombus formation with potential for 
embolization, fatigue, palpitations, hypotension, myocardial ischemia and tachycardia-
induced myocardial dysfunction.  One of the most significant consequences is cerebral 
artery embolization – which occurs at an approximate rate of “[five] events per 100 
patient years.”1 
Atrial fibrillation is a disease that tends to present more in later life1 and is the 
most common arrhythmia in the elderly.2  Dr. Alan Go and colleagues3 in their 
“Anticoagulation and Risk Factors In Atrial Fibrillation” (ATRIA) study found that only 
0.1% of individuals less than 55 years of age are affected by AF.  The impacted 
population increases to 9.0% in those above the age of 80.3  As the occurrence of AF 
increases with age, so do the potential co-morbidities.  The risk of stroke increases to 
“nearly 20 events per 100 patient years” in individuals affected by AF with multiple risk 
factors – including age greater than 75 years, significant obstructive valvular disease, 
chronic heart failure, left ventricle dysfunction, diabetes and/or hypertension.1 
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In addition to the increased incidence of AF, the elderly population has a much 
higher likelihood of complications secondary to age-related decline in bodily function.  
For example, approximately 50% of patients hospitalized for gastrointestinal (GI) 
hemorrhage are over the age of 60.4  The incidence of intracerebral hemorrhage is also 
associated with advancing age.5  Likewise, the geriatric population has a higher fall risk, 
with roughly 1/3 of individuals greater than 65 falling each year.6  The CHADS2 score 
was developed as a measuring standard to determine an individual’s risk of stroke 
secondary to major concomitant conditions and determining when a patient might benefit 
from anticoagulation therapy (Table 1).7  While this score is used daily in clinical 
practice, it does not take into account the risk of potential morbidity and mortality to a 
patient while on anticoagulants. 
One of the primary anticoagulants used in the management of AF is warfarin.  
Although warfarin has been shown to significantly reduce the risk of stroke in patients 
with AF,8 it also potentiates an increased risk of bleeding, especially following 
commencement of use or with higher doses.9 
Practitioners are faced with the determination of this benefit versus risk in their 
geriatric patients, yet, there are no standards delineating the guidelines for warfarin 
therapy in the elderly.  The purpose of this study was to evaluate the risk of 
complications, primarily hemorrhage, in the elderly population with atrial fibrillation 
secondary to treatment with warfarin therapy; with the goal of decreasing the confusion 
associated with placing elderly patients affected by atrial fibrillation on warfarin. 
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METHODS 
Search Strategy 
 
A comprehensive literature search was completed in order to compose this 
systematic review.  Multiple search engines and databases were used, including Medline, 
CINAHL and EBMR Multifile using the search words “Aged”, “Atrial Fibrillation”, 
“Mortality” and “Warfarin”.  One hundred thirty-seven articles were found initially 
through the three major databases, with eight additional articles found in reference 
materials.  Duplicates were removed and articles were screened for relevance.  A total of 
17 full text articles were assessed, with 13 articles excluded for lack of relevance to the 
specified population or management specifications (Figure1). 
Validity Scoring 
 The validity of each article was assessed on a scale of eight self-determined 
validity criteria.  Articles received one point for every criterion met.  The criteria 
consisted of having a patient population greater than 100, a study duration greater than 
six months, more than one study group, the inclusion of statistical analysis, the inclusion 
of withdrawal or dropout patients, comparison of warfarinised versus non-warfarinised 
patients, comparison of two or more age groups and refraining from the use of financial 
support from drug-associated parties (Table 2). 
Inclusion Criteria 
English Language, human only, population >70 years of age, individuals with 
atrial fibrillation, use of warfarin therapy versus no anticoagulant therapy and discussion 
of morbidity, mortality or hemorrhage.   
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Some studies, of the available few, contained irrelevant information which was 
not considered substantively in this review.  All relevant findings were analyzed fully. 
*One study10 analyzed only warfarin users broken into two age categories. 
*One study11 examined medical information from a population composed of only 
warfarin users.  This study looked at the group collectively and did not 
differentiate comparison groups. 
*One study12 evaluated patients in three groups, warfarin users, warfarin non-
users and other anticoagulant users.  This systematic review did not analyze data 
from the other anticoagulant group but did take into consideration the segments 
discussing the first two categories. 
Exclusion Criteria  
Studies referring to anticoagulation therapy following ablation therapy or other 
surgical forms of AF management, inclusion of patients with mechanical heart valves, 
inclusion of patients with target International Normalized Ratio (INR) > 3 or study 
populations that were too narrowly drawn. 
*One study13 found maintained a focus of increasing age in their evaluation of the 
risk of oral anticoagulants, however, this study included patients with mechanical 
heart valves and patients with target INR >3, and thus, the paper in its entirety, 
was not include in this systematic review. 
RESULTS 
All four articles assessed were observational studies, with no randomized 
controlled trials.  In total, 14 342 patients were analyzed between 1996 and 2007, with 
the largest cohort consisting of 13 559 patients and the smallest of 220 patients.  Study 
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duration ranged from six months to 28 months.  All studies took into account age or 
frailty in elderly patients with AF, with either a total patient population or at least one 
study group utilizing warfarin therapy.  A condensed version of the details from each 
article, in addition to their findings and validity score can be found in Table 3 in the 
Article and Results Summary Matrix. 
Age and the Risk of Warfarin-Associated Hemorrhage: The ATRIA Study 
 Dr. Margaret Fang and colleagues14 used the ATRIA cohort of 13 559 patients to 
determine the risk of warfarin-associated hemorrhage in AF patients stratified by age.  
Study information was gathered from hospitalization and billing databases.  Patients were 
recruited between July 1, 1996 and December 31, 1997 and followed until August 31, 
1999.  Patients were separated into four categories: <60, 60-69, 70-79 and >80.  Only 
those with a diagnosis of non-valvular, non-transient AF were evaluated.  For those 
taking warfarin, INR intensity and variability were taken into account.14 
Hemorrhage was assessed as intracranial or extracranial.  Major extracranial 
hemorrhages included those which were fatal, required two or more transfusions or 
involved bleeding into a critical anatomic site.  Patients were followed for an average of 
2.4 years.  The mean age was 71, with 28% of the documented patient years obtained 
from those over the age of 80.14 
 Fang et al14 found INR intensity and variability remained consistent between age 
groups.  They also determined “[t]he rate of all major hemorrhage rose with older age” 
regardless of warfarin use; with a significant increase in both intracranial and extracranial 
hemorrhage in patients over the age of 80.14 
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 With regard to age categories, Fang et al14 noted an “average relative increase in 
the rate of hemorrhage from one age category to the next older age category was 1.3 
(95% CI=1.1-1.6)” in warfarinised patients and 1.7 (95% CI = 1.5-2.1) in non-
warfarinised patients.  After adjusting for potential hemorrhage risk factors, the “relative 
increase in hemorrhage rate in warfarin users was 1.2 (95% CI=1.0-1.4)” and 1.5 (95% 
CI=1.3-1.8) for non-warfarin users.  Lastly, Fang and colleagues14 resolved that “patients 
newly started on warfarin may be more likely to suffer hemorrhagic complications.” 
 Overall, there was no statistically significant difference in the occurrence of 
hemorrhage between patients taking warfarin and those not.  They concluded that “well-
managed warfarin therapy can be used safely in clinical practice to achieve substantial 
benefit in reducing the risk of atrial fibrillation-associated ischemic stroke.”14 
Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population 
With Atrial Fibrillation 
 The 2001 study by Copland and colleagues10 assessed the quality of 
anticoagulation control and the incidence of hemorrhage between two age groups, both 
receiving warfarin therapy, with target INR of 2.5 via retrospective follow-up.  
Secondarily, they evaluated these same factors in patients newly started on warfarin 
therapy versus long-term warfarin users.  In total, 328 patients were followed from 
January 1, 1998 to September 30, 1999, with 204 in the control group aged 60-69 (mean 
age 64.7), and 124 in the elderly study group age >75 (mean age 78.3).  All individuals 
included at the commencement of the study were accounted for at its finale.10 
 A major hemorrhage was defined as a fatal bleeding incidence, bleeding involving 
the central nervous system or bleeding requiring hospitalization, surgery or blood 
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transfusions.  The incidence of major hemorrhage was 2.8% in the control group and 
2.9% in the elderly group (P=0.96).  Of those, the incidence of intracranial hemorrhage 
was 0.7% in the control group and 1.2% in the elderly group (P=0.61).  INR levels were 
maintained within the therapeutic range for 66.1% of the control group and 71.5% of the 
elderly group (P=0.13).10 
 As an additional note, INRs remained within target range in 62.1% of new 
warfarin users compared with 70.9% in long-term warfarin users (P<.005).  The 
incidence of major hemorrhage was also significantly higher in the new-user group.10 
 In conclusion, Copland et al10 determined there was no statistically significant 
variation in INR control or risk of major hemorrhage between patients in the 60-69 age 
group and those greater than 75 years of age with atrial fibrillation on warfarin therapy. 
Secondly, INR variability and incidence of major hemorrhage were statistically more 
likely in new warfarin users compared with long-term users.10 
People Aged Over 75 in Atrial Fibrillation on Warfarin: The Rate of Major 
Hemorrhage and Stroke in More Than 500 Patient-Years of Follow-Up 
In their Australian retrospective observational cohort study, Johnson and 
colleagues11 set out “[t]o determine the incidence of major hemorrhage and stroke in 
people” over the age of 75 recently admitted to the hospital having the diagnosis of AF.  
A total of 235 patients were evaluated over an average period of 28 months.  The study 
population was composed of patients with a discharge diagnosis of AF who had been 
started on warfarin via the inpatient pharmacy between July 1, 2001 and June 30, 2002 in 
four tertiary care hospitals.  The mean age of the patient population was 81.1.  All 235 
patients were accounted for at the conclusion of this study, including 7 drop outs.  
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Findings were reported as percentages.  No statistical analysis was completed.  
Additionally, participants were collectively evaluated, with no comparison groups 
delineated.11 
Throughout this study, major bleeding episodes, strokes and warfarin use were 
measured by examining data from patients, relatives, physicians and medical records.  
Major hemorrhage was qualified in three categories, serious, which included 
hemorrhages resulting in hospital admission, a 2g/dL drop in hemoglobin or requiring no 
more than two units of blood; life-threatening, which included hemorrhages involving the 
central nervous system, causing a greater than 2 g/dL decrease in hemoglobin, requiring 
more than two units of blood, causing systolic hypotension, resulting in cardiopulmonary 
arrest or requiring an emergent procedure; and, lastly, fatal major hemorrhages.11  
The study population was initially drawn from 933 patients with an age >75 and a 
diagnosis of AF.  Only 25% of these individuals were prescribed warfarin during their 
hospital stay and thus were included in this study.  As a result, Johnson and colleagues11 
deduced that warfarin is under-prescribed for the elderly population diagnosed with AF. 
Johnson et al11 reported an annual major hemorrhage rate of 10% in the study 
population.  Of these, 45.3% were serious, 45.3% were life-threatening and 9.4% were 
fatal.  The annual rate of fatal hemorrhage was 0.9%.  The predominant major 
hemorrhages presented as GI bleeds (30.2%), with a small subset of reported intracranial 
hemorrhages (0.4%).  Of note, 54.7% of all hemorrhages reported, were in patients with 
elevated INRs (>3).11 
 14 
Throughout this study11, a total of 17 strokes were documented.  At the time of 
stroke, 29.4% of participants had a therapeutic INR (INR >2), while the remaining 70.6% 
were subtherapeutic (INR <2).11 
Johnson and colleagues11 discovered the risk of major hemorrhage was substantial 
in elderly patients with AF on warfarin therapy.  They found, however, that the 
hemorrhages did not pose long-term sequelae when compared to the benefit of stroke 
reduction, concluding warfarin therapy was a safe and effective method of stroke 
prevention for elderly patients.11 
The Impact of Frailty on the Utilization of Antithrombotic Therapy in Older 
Patients With Atrial Fibrillation 
In Perera and colleagues12 study, between April and July 2007, individuals greater 
than 70 years of age with an admission diagnosis of AF in a Sydney, Australia hospital 
were invited to participate.  Medical records were evaluated at time of admission, and 
again at three months and six months.  All participants were accounted for at the 
conclusion of the study, including drop out patients.  Individuals were analyzed in two 
groups, frail and non-frail.  They were also broken into subgroups including patients on 
warfarin therapy, non-warfarin anticoagulant therapy and no anticoagulant therapy.  A 
total of 220 patients were evaluated and 207 followed for the full six month duration.  
Ninety-eight participants were designated as other anticoagulant users and were not 
included in this systematic review.12 
Stroke incidents were classified as cardioembolic or other.  Hemorrhages were 
recorded in three categories: minor (not requiring hospitalization), major (requiring 
hospitalization) or severe (intracranial or fatal).  Frailty was determined via a modified 
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Edmonton Frail Scale with consideration of age, nutritional deficits, decreased mobility, 
disease, social withdrawal, poor income, number of hospitalizations and cognitive 
impairment.12 
Using the Kaplan-Meier survival function, Perera and colleagues12 determined 
that frail patients seemed to have an elevated risk of major/severe hemorrhage compared 
to non-frail, but the difference was not statistically significant (HR=1.35, P=0.34).  “The 
incidence of major/severe hemorrhage over 6 months was 30.0% in the frail and 18.9% in 
the non-frail participants prescribed warfarin” compared to “8.3% for frail and 0% for 
non-frail participants receiving no antithrombotic therapy.”  The sample size was too 
small to determine statistical significance of antithrombotic modalities.12 
In evaluation of prescribing practices, frail patients were “significantly less likely 
to receive warfarin than non-frail on admission or discharge” based on the prescribing 
practices of three different specialty groups in the hospital.  They also deduced frail 
patients had a higher probability of cardioembolic stroke (HR=3.37, P=0.04) and death 
(HR 2.62, P=0.009) than non-frail.12 
Perera et al12 concluded frailty is a determining factor in whether or not 
individuals with AF are prescribed warfarin.  Secondly, the risk of hemorrhage is high in 
frail patients regardless of warfarin use, and frail patients are significantly more likely to 
experience stroke or death compared with non-frail.  Lastly, they noted further research is 
recommended to determine the statistical significance of the affect of warfarin therapy in 
frail patients.12 
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DISCUSSION 
Overview 
The intent of this systematic review was to examine the morbidity and mortality 
associated with warfarin therapy in elderly patients with AF.  The initial literature search 
was aimed to find studies which evaluated the use of warfarin therapy compared with no 
anticoagulant therapy in patients greater than 70 years of age diagnosed with non-
valvular, non-transient AF.  A significant number of articles found addressed these 
issues, however, only a handful were focused on the geriatric population.  Due to this, the 
inclusion and exclusion criteria were broadened, in order to incorporate all relevant 
articles focused on the elderly.  For the purpose of this review, relevant findings were 
fully analyzed, while irrelevant information was disregarded. 
Validity 
 Validity criteria consisted of having a patient population greater than 100, a study 
duration greater than six months, more than one study group, the inclusion of statistical 
analysis, the inclusion of withdrawal or dropout patients, comparison of warfarinised 
versus non-warfarinised patients, comparison of two or more age groups and refraining 
from the use of financial support from drug-associated parties (Table 2). 
The study by Fang et al,14 was the only study to comply with the inclusion and 
exclusion criteria initially comprised for this review.  Participants were assigned to two 
study groups, warfarin-users or non-users, and subdivided into four age categories.  This 
study was given a validity score of 7/8 secondary to the fact that a primary author 
received funding from the drug company which produces Coumadin, the brand name of 
warfarin.   
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The Copland et al10 study only evaluated patients taking warfarin, but 
differentiated the study population into two groups based on age.  Furthermore, the study 
did not include a discussion regarding financial contributions, and thus potential for bias 
could not be determined.  As a result, the study received a validity score of 6/8. 
Johnson and colleagues11 scored a total of 4/8 on the validity scale.  Their study 
did not contain multiple study groups, it failed to include statistical analysis, it did not 
compare between warfarin-users and non-users, and finally, it did not include two or 
more age groups.  Not only did this study fail to provide statistical analysis, it did not 
supply enough raw data for the reader to calculate such results.  Characteristics of the 
cohort were detailed in a table, yet, these factors were not associated with individual 
results.  In observing all warfarinised all elderly patients, the reader can gain some insight 
into hemorrhage rates in this population; however, it is difficult, if not impossible, to 
analyze these findings without some form of comparison.11 
The Perera et al12 study evaluated patients as frail or non-frail.  While this 
determination included the aspect of age, it did not evaluate age independently, resulting 
in a validity score of 7/8.  Authors assessed patients in the subgroups of warfarin-users, 
non-warfarin anticoagulant users and non-anticoagulant users.  The 98 patients belonging 
to the group utilizing non-warfarin anticoagulants were excluded from analysis in this 
systematic review.  With the removal of these participants, the study population was 
deduced from 220 to 122, close to the validity cutoff for this review.  A total of 83 
patients remained in the warfain group, with only 26 patients in the non-anticoagulant 
therapy group.   
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Warfarin Prescribing Practices 
Two studies commented on the prevalence of warfarin prescriptions in AF 
populations.  While Johnson and colleagues11 concluded that warfarin prescription was 
decreased in light of increasing age or frailty, this observational study evaluated patients 
collectively, without separating study groups based on age, frailty or any other factor.  
Subsequently, it is difficult to determine how this conclusion was drawn.  This result 
would be more beneficial if providers were screened for prescribing reasons, perhaps 
including age, frailty, hemorrhage risk, fall risk or other, while tracking patient 
demographics. 
In their findings, Perera et al12 noted a significant decrease in warfarin 
prescriptions among frail patients compared to non-frail patients.  While these findings 
were consistent across three prescribing specialties (geriatric medicine, general medicine 
and cardiology), explicit reasons for the decreased prescriptions were not available 
secondary to the retrospective nature of their study.  Again, prescriber rationale would be 
extremely helpful for future research regarding the production of standardized prescribing 
guidelines for warfarin in the elderly patient with atrial fibrillation. 
Variation in INR With Age 
 With regard to INR control, two studies10, 14 concluded there was no variation in 
INR levels between age groups.  Patients in both studies10, 14 were monitored closely via 
anticoagulation clinics, which may have decreased the likelihood of variation in this 
population.  While maintaining an INR within the therapeutic range is imperative, doing 
so at a specialized anticoagulation clinic is a luxury that may not be available for all 
elderly patients with AF. 
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Hemorrhage, Stroke and Death Risk With Increasing Age 
 Fang et al14 concluded that hemorrhage and stroke risk increase with age, 
independent of warfarin use.  Similarly, Perera and colleagues12 found a significant 
increase in stroke and death rate and a non-significant increase in hemorrhage rates 
among frail versus non-frail patients regardless of the anticoagulant method.  These 
findings are expected and correlate with the increased risk of GI4 and intracerebral5 
hemorrhage with age; as well as the increased stroke risk in patients with AF associated 
with increasing age discussed in other sources.1 
Hemorrhage Risk With Warfarin and Increasing Age 
 Hemorrhage risk in relation to Warfarin use with increasing age was one of the 
main focuses of this systematic review.  Two studies10, 14 determined there was no 
variation in hemorrhage risk with warfarin use in relation to increasing age.  This finding 
is surprising and counterintuitive, considering the primary side effect of warfarin is 
hemorrhage9, that over 50% of patients hospitalized for GI bleeds are over the age of 604 
and the fact that advancing age is associated with intracerebral hemorrhage.5  Many 
factors, not accounted for in these studies, may have affected the results.  One 
explanation may be the duration of warfarin use between age groups.  New warfarin-
users are more likely to experience adverse bleeding effects.9  Perhaps the older age 
group had been on warfarin for a longer duration than the younger group.  Findings may 
also be explained by the close INR monitoring, or secondary to a smaller study 
population of only 328 patients in the Copland et al10 study. 
The study by Johnson and colleagues11 noted the prevalence of hemorrhage was 
high but posed minimal long-term sequelae.  No details were included regarding the 
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evaluation of long-term stroke or hemorrhage effects.  This conclusion would be more 
applicable if the authors had included specific long-term complications or lack there of, 
such as paralysis following stroke or continued anemia following hemorrhage. 
Perera and colleagues12 displayed evidence of an increased hemorrhage risk in 
both the non-frail and frail warfarin-users compared to non-users, however, their study 
population was too small to determine statistical significance.  These findings are 
consistent with the increased hemorrhage risk with age discussed above.  Additional 
research is necessary to confirm or refute results found in all four articles. 
New Warfarin Users 
Fang et al14 found a non-significant increased risk of hemorrhage in new warfarin 
users.  Similarly, Copland and fellow authors10 noted that hemorrhage risk and INR 
instability were both increased in patients newly started on warfarin.  This was expected 
and complies with the adverse drug reactions noted in warfarin drug information 
sources.9  These findings only reiterate the necessity of close INR monitoring, especially 
with initiation of the anticoagulant warfarin. 
Non-Therapeutic INR 
Authors of the Johnson et al11 study stated stroke rates increased with 
subtherapeutic INRs and hemorrhage rates increased with supratherapeutic INRs.  This 
information follows the general thinking behind warfarin therapy, and the need for 
closely-monitored INR levels, however, these findings are only generalized conclusions 
without the inclusion of statistical findings, which were non-existent in this study. 
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Study Limitations 
The primary limitation shared by all four articles10-12, 14 assessed was the fact that 
each study took an observational approach.  As a result, prescribing practices were 
unobtainable.  Prescribing physicians may have avoided warfarin therapy in the very frail 
or very old, limiting the absolute applicability of each study to the generalized elderly 
population.   
A secondary shared limitation10-12, 14 is the potential for non-documented 
concomitant use of over-the-counter anticoagulants, such as aspirin or NSAIDs.  While 
one study14 evaluated a subset of the population for other anticoagulant use, and another12 
had a study group who only used non-warfarin anticoagulants, authors were limited in 
that they could not monitor or record what over-the-counter medications patients had 
consumed.  There may be some overlapping effect secondary to these non-prescribed 
anticoagulants on the overall hemorrhage rate in the study populations. 
A few studies had shared limitations which were not universal to all articles 
assessed.  Both the Johnson et al11 and Perera et al12 studies were based on a populace of 
Australian individuals, and thus may not be as applicable to American patients with 
respect to potential variation in genetic and environmental factors affecting coagulation.  
The Fang et al14 and Copland et al10 studies evaluated a population of patients monitored 
closely via anticoagulation clinics.  Although this supervision is ideal, it may not reflect 
the general population with regard to INR stability and control. 
On an individual note, the Fang et al14 study was partially funded by the makers 
of Coumadin, the brand name of warfarin.  While this does not necessarily indemnify the 
findings associated with this study, it does pose a potential for bias.   
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Likewise, the Copland et al10 study did not note financial contributors and thus 
may also be subject to bias.  Additionally, the study10 did not compare the incidence of 
hemorrhage between patients not taking warfarin and those who were.  Although this is 
not a significant downfall, it does limit the applicability in the debate between initiating 
anticoagulation therapy in the older AF patient and not.   
The majority of limitations associated with the Johnson and colleagues11 study 
have been alluded to under the validity section of this discussion.  The lack of study 
groups, and subsequently, statistical analysis drawn through comparison makes this 
article nearly irrelevant.  It was impossible to determine the effect of warfarin in AF 
patients of increasing age, a primary goal of this systematic review. 
While their information was helpful in light of general prescribing practices in 
elderly patients with AF, Perera and colleagues12 study population was too small to 
determine a significant difference in hemorrhage or stroke risk between warfarin users 
and non-users.  This systematic review did not evaluate the non-warfarin anticoagulant 
group, which further decreases the study population size. 
CONCLUSION 
Throughout this systematic review, four relevant articles were identified and 
evaluated.  Each article addressed the aspect of prescribing warfarin in elderly patients 
with atrial fibrillation.  This review demonstrated that elderly and frail individuals are at 
greater risk for stroke and hemorrhage regardless of anticoagulant use.  The use of 
warfarin therapy did not prove to be more harmful than no therapy in elderly or frail 
patients with atrial fibrillation according to these studies.  Similarly, the risk of 
hemorrhage associated with warfarin did not vary statistically between age groups.   
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Additional research is necessary in order to develop prescribing guidelines with 
regard to advancing age/frailty and warfarin therapy.  These studies would be most 
effective as randomized controlled trials without funding from drug-associated 
companies, which would limit physician bias in warfarin non-prescriptions for the very 
frail or very old and reduce the potential for study bias.   
Anticoagulation with warfarin has been proven to significantly reduce the risk of 
stroke.  While placing an individual on anticoagulants poses potential risk for increased 
bleeding, the benefit of stroke prevention outweighs the risk.  Regardless of prescribing 
guidelines, it is imperative that warfarin be prescribed and monitored carefully in all age 
ranges in order to provide the most effective prevention of embolic stroke while 
minimizing the risk of hemorrhage and other deleterious effects. 
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TABLES 
 
Table 1 – CHADS2 Score and Interpretation 
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Figure 1 – Article Selection for this Systematic Review 
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